Management of Recipients of Hepatic Allografts Harvested from Donors with Malignancy Diagnosed Shortly after Transplantation by Detry, Olivier et al.




MANAGEMENT OF RECIPIENTS OF HEPATIC ALLOGRAFTS  
HARVESTED FROM DONORS WITH MALIGNANCY  
DIAGNOSED SHORTLY AFTER TRANSPLANTATION 
 
Olivier Detry, Pierre Honoré, Nicolas Jacquet, Michel Meurisse 
Department of Surgery and Transplantation 
CHU Sart Tilman, Liège, Belgium 
Running title: Cancer in liver graft 
 
Computer System: Macintosh OS 8, Microsoft Word 6.0 
 
Olivier Detry MD, Department of Transplantation, CHU Sart Tilman B35,  
B-4000 Liège, Belgium 
Phone: 32/43667206 Fax: 32/43667517 Email: Oli.Detry@chu.ulg.ac.be 




Detry O, Honoré P, Jacquet N, Meurisse M. Management of recipients of hepatic allografts 
harvested from donors with malignancy diagnosed shortly after transplantation. 
Clin Transplantation 
Abstract: Transmission of undiagnosed malignancy with the graft is a dramatic complication 
of liver transplantation. Alternatives in the management of the recipients of livers harvested 
from donors with malignancy diagnosed shortly after transplantation, are either early 
retransplantation or close follow-up without reoperation.. We reported four cases of liver 
recipients whose allografts were harvested from donors who were diagnosed with 
malignancy shortly after the liver transplantation. One recipient underwent retransplantation, 
and the three other allografts were not removed. No recipient developed recurrence in the 
follow-up. While graft removal may be the only way to avoid tumor recurrence in recipients 
of liver graft harvested from donor with malignancy, close follow-up without reoperation 
may also be considered. The risk of tumor transferral may depend on the histopathological 
aggressiveness an metastatic potential of the donor tumor, and may be low for low-grade, 
local tumors. This risk should be evaluated by analysing large series, using databases of 
Eurotransplant or United Network for Organ Sharing. 
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Malignancy transmission from the donor to the recipient is a rare but dramatic complication 
of solid organ transplantation. In our institution, one kidney and one liver recipient both 
developed recurrence of an undiagnosed choriocarcinoma that led to donor's death (1). 
Since these two cases, we have received from Eurotransplant two liver allografts which 
were harvested from donors with undiagnosed malignancy, and that were transplanted in 
our institution. We also diagnosed a renal-cell carcinoma in a renal graft, whose 
corresponding liver was split and transplanted into two recipients in two other centers.  
Management of the recipients of liver allografts harvested from donors with malignancy 
diagnosed shortly after transplantation, has not been established because only a few cases 
have been reported in the literature. The alternatives are either early retransplantation or 
close follow-up without reoperation in order to detect any recurrence. Based on our first 
unfortunate experiences and on the literature (2), we initially recommended early 
retransplantation (1). We successfully applied this policy in a recipient of a liver whose 
donor was later diagnosed with a disseminated epidermoid epithelioma. However, we 
recently chose not to retransplant the recipient of a liver graft harvested from a donor with 
undiagnosed renal-cell carcinoma. The purpose of this paper was to report these cases and 
to explain the changes in our management policy. 





Recipient 1  
In June 90, Eurotransplant sent us an hepatic allograft harvested from a 35-year-old female 
donor, who had died from spontaneous cerebral hemorrhage. We transplanted this graft into 
a 25-year-old recipient. Donor autopsy was performed the day after the harvest. This 
autopsy and the histopathological examination of several lymph nodes demonstrated a 
disseminated, invasive, epidermoid epithelioma originating from the cervix uteri (1). The 
recipient was then screened for gross tumor involvement of the liver graft using 
ultrasonography and computed tomography. No evidence of tumor was showed. The 
patient was listed for emergent retransplantation and underwent a second orthotopic liver 
transplantation (OLT) seven days after the first transplantation. No evidence of any 
malignant process was detected during the reoperation and on histopathological 
examination of the explanted liver. The patient remained free of recurrence at the 7-year 
follow-up. 
Recipients 2 and 3.  
In August 96, we received from Eurotransplant a kidney graft harvested from an 18-year-
old donor who had died from head trauma. The multiorgan procurement had been 
uneventful. We discovered a 2 mm renal-cell carcinoma in this kidney, and the 
transplantation was cancelled. However, at the time of histopathological diagnosis, the liver 
from this donor had already been split and transplanted into two recipients in two different 
institutions. Despite this diagnosis, the liver grafts were not removed. These two recipients 




remained free of recurrence at the 1-year follow-up, as established by telephone contact 
with the institutions where the organs were transplanted. 
Recipient 4.  
In October 97, we received a liver allograft harvested from a 54-year-old male donor who 
had died from spontaneous subdural hemorrhage. We transplanted this liver into a 49-year-
old male recipient. Shortly after graft reperfusion, the procurement team announced the 
discovery of an 8 mm renal-cell carcinoma in the right kidney. We carefully examined the 
liver graft, and performed an intraoperative ultrasonography. No evidence of metastasis 
was found and the OLT was completed. After discussion, we decided not to remove this 
graft. This recipient died from graft versus host disease 7 months after OLT. No evidence 
of tumor recurrence was found at autopsy and on histopathological examination of the liver. 





The first reports of malignancy transferral with solid organ transplantation were published 
in the 1960's, when the risks of cancer transmission into immunosuppressed patients were 
not known (2). Today, it has become obvious that the immunosuppressive treatment 
enhances the risk of tumor recurrence in recipients of organs harvested from donors with 
malignancy (3). Therefore, with the relative exception of the primary central nervous 
system tumors (2,4,5), patients with recent known history of malignancy are actually 
rejected for organ donation. Moreover, donors should be carefully screened for 
undiagnosed or infraclinic malignancy (1,6). Based on our unfortunate experience of tumor 
transferral in two recipients, we recommended a severe policy of tumor detection in the 
donor (1), based on (a) the careful examination of the donor during procurement; (b) the 
immediate frozen section of any suspicious lesion; (c) intraoperative ultrasonography of 
liver and kidney grafts; (d) donor autopsy; (e) beta-human chorionic gonadotrophin 
(ßHCG) screening in all female donors in child bearing age, in order to diagnose 
choriocarcinoma. Using this policy, we recently discovered a undiagnosed renal-cell 
carcinoma in a donor who had died from spontaneous cerebral hemorrhage, and we 
cancelled the procurement (6). However, this policy can not completely avoid 
transplantation of grafts harvested from donors with undiagnosed malignancy because (a) 
some tumors can be too small to be diagnosed by examination or intraoperative 
ultrasonography (7); (b) immediate frozen sections are not available in every procurement 
hospital, and/or their results may be communicate to late (1,7); (c) intraoperative 
ultrasonography is not available in many community hospitals (7); (d) permission for donor 
autopsy is seldom given (7); (e) ßHCG testing is not available in every hospital (7); (f) the 




organ donor shortage has lead to the use of "suboptimal" and/or older donors, whose risk of 
undiagnosed malignancy is increased (6); (g) the thoracic organs are usually harvested and 
transplanted prior to any extensive donor dissection (8). Consequently, there will always be 
sporadic cases of transplantation of grafts harvested from donors with undiagnosed 
malignancy. 
Management of the recipients of liver grafts harvested from donors with malignancy 
diagnosed shortly after the OLT, can be a matter of debate. The alternatives are either early 
removal of the liver graft and recipient retransplantation (2), or close follow-up without 
reoperation. Based on our experience, we initially recommended early retransplantation (1). 
We successfully applied this policy in Recipient 1, who was still alive without recurrence at 
the 7-year follow-up. However, we did not find evidence of malignancy in the explanted 
graft, and it is likely that this recipient could have remained tumor free without reoperation. 
In Recipients 2 and 3, the surgeons who transplanted the two parts of the corresponding 
liver did not retransplant the recipients despite our diagnosis of renal-cell carcinoma in a 
kidney graft. Recently, we chose not to retransplant Recipient 4, despite the evidence of an 
8 mm renal-cell carcinoma in the donor. This policy change may seem controversial, 
because early retransplantation could be the only way to avoid malignancy recurrence in 
the recipients. However, retransplantation should be recommended only if the benefits in 
the decrease in the risk of tumor recurrence are greater than the risks and the costs of the 
retransplantation.  
It is difficult to estimate the risk of malignancy transmission after transplantation of a liver 
graft harvested from a donor with malignancy. This risk depends certainly on several 
factors, as the type, the size and the grading of the tumor, as well as the type of post-




transplantation immunosuppressive regimen. It is well known that the liver is a usual 
metastasis site and the risk of recurrence after liver transplantation is therefore irrefutable. 
For instance, it is estimated that more that 25 percent of patients with renal-cell carcinoma 
have metastases at the time of diagnosis, and that the liver is a site of metastasis in 30 to 40 
percent of the cases (9). Since the 1960's, the Cincinnati Transplant Tumor Registry 
(CTTR) has collected reports of tumor occurring in transplanted patients. The CTTR has 
also recorded the discoveries of malignancy in organ donors, including primary brain 
tumors. According to this registry, 248 recipients received organs from such donors up until 
1995, and 103 of these recipients (42%) developed tumor recurrence (7). However, we 
believe that the overall risk of recurrence after OLT is still unknown. Most of the CTTR 
cases involve kidney grafts. As a matter of fact, up until 1995, only 10 liver recipients 
whose organ donors were diagnosed with malignancy, were listed in the CTTR (7). 
Furthermore, the high recurrence rate reported by the CTTR may be biased, as it is easier to 
report a complication, such as tumor transferral, than to report the absence of complication, 
such as the absence of tumor transferral. In the absence of study on the outcome of 
recipients of liver harvested from donors with undiagnosed malignancy, we consider that 
the risk of tumor transferral with liver graft is still unknown. This risk may be lower than 
previously published and may depend on the histopathologic aggressiveness and metastatic 
potential of the donor tumor. This risk may be moderate for local, low-grade tumors, or if 
the intraoperative ultrasonography of the liver graft shows no evidence of metastasis. 
The immediate removal of the liver graft after diagnosis of donor's tumor can not avoid the 
risk of tumor recurrence from malignant cell seeding and dissemination at the time of graft 
reperfusion. The risks and the costs of early retransplantation must also be considered. The 




morbidity and the mortality of reoperation is not negligible. Retransplantation also 
consumes an additional liver allograft, during a time when many patients awaiting for OLT 
are dying because of the organ shortage. For all these reasons, early retransplantation may 
appear to be a costly and high risk procedure, whose effectiveness for avoidance of tumor 
recurrence has yet to be established. 
In conclusion, removal of a liver graft harvested from a donor with malignancy diagnosed 
shortly after OLT, may be the only way to avoid tumor recurrence in the recipient. 
However, in the absence of study demonstrating the efficacy of early retransplantation, 
close follow-up without reoperation is certainly an alternative, especially for low-grade, 
local tumors. The risk of tumor transferral should be studied by analysing the outcome of 
large series, using the databases of Eurotransplant or the United Network for Organ 
Sharing. Such a study could lead to a rational scientific approach to the management of 
recipients of hepatic allografts harvested from donors with undiagnosed malignancy. 
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